DOP2023000090A - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents

Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Info

Publication number
DOP2023000090A
DOP2023000090A DO2023000090A DO2023000090A DOP2023000090A DO P2023000090 A DOP2023000090 A DO P2023000090A DO 2023000090 A DO2023000090 A DO 2023000090A DO 2023000090 A DO2023000090 A DO 2023000090A DO P2023000090 A DOP2023000090 A DO P2023000090A
Authority
DO
Dominican Republic
Prior art keywords
cyclopentathiophen
receptor antagonists
factor receptor
platelet activation
carboxamide derivatives
Prior art date
Application number
DO2023000090A
Other languages
English (en)
Spanish (es)
Inventor
Wiedenmayer Dieter
Thomas Leo
Prestle Juergen
Eckhardt Matthias
Kristina Willwacher Marina
Kontes Ferenc
Siegfried Tautermann Christofer
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of DOP2023000090A publication Critical patent/DOP2023000090A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
DO2023000090A 2020-11-16 2023-05-11 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas DOP2023000090A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20207719 2020-11-16
PCT/EP2021/081459 WO2022101377A1 (en) 2020-11-16 2021-11-12 Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Publications (1)

Publication Number Publication Date
DOP2023000090A true DOP2023000090A (es) 2023-06-15

Family

ID=73543025

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2023000090A DOP2023000090A (es) 2020-11-16 2023-05-11 Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas

Country Status (19)

Country Link
US (2) US11766443B2 (https=)
EP (1) EP4244229A1 (https=)
JP (2) JP7465368B2 (https=)
KR (1) KR20230109692A (https=)
CN (2) CN116745300A (https=)
AR (1) AR124070A1 (https=)
AU (1) AU2021379248A1 (https=)
CA (1) CA3200710A1 (https=)
CL (2) CL2023001361A1 (https=)
CO (1) CO2023005894A2 (https=)
CR (1) CR20230211A (https=)
DO (1) DOP2023000090A (https=)
EC (1) ECSP23036210A (https=)
IL (1) IL302769A (https=)
JO (1) JOP20230107A1 (https=)
MX (1) MX2023005678A (https=)
PE (1) PE20231855A1 (https=)
SA (1) SA523440809B1 (https=)
WO (1) WO2022101377A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119842821A (zh) * 2025-01-06 2025-04-18 华中科技大学 稳定表达血小板活化因子受体的细胞株、构建方法及应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3502392A1 (de) 1985-01-25 1986-07-31 Boehringer Ingelheim KG, 6507 Ingelheim Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen
IE870123L (en) * 1986-01-21 1987-07-21 Boehringer Ingelheim Int Thieno-1,4-diazepines
PH30676A (en) 1986-07-22 1997-09-16 Boehringer Ingelhein Kg Hetrazepine compounds which have useful pharmaceutical utility
US4959361A (en) * 1987-12-18 1990-09-25 Hoffmann-La Roche Inc. Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
DE3909012A1 (de) 1989-03-18 1990-09-20 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen
DE4010528A1 (de) 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine
DE4132763A1 (de) 1991-10-02 1993-04-08 Boehringer Ingelheim Kg Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur
FR2779652B1 (fr) 1998-06-15 2001-06-08 Sod Conseils Rech Applic Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
CA2670031A1 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors

Also Published As

Publication number Publication date
CN117624188A (zh) 2024-03-01
CR20230211A (es) 2023-07-13
CN116745300A (zh) 2023-09-12
US20220160725A1 (en) 2022-05-26
WO2022101377A1 (en) 2022-05-19
US20230355638A1 (en) 2023-11-09
CO2023005894A2 (es) 2023-05-29
ECSP23036210A (es) 2023-06-30
AR124070A1 (es) 2023-02-08
JP2024099528A (ja) 2024-07-25
KR20230109692A (ko) 2023-07-20
TW202237620A (zh) 2022-10-01
JP7465368B2 (ja) 2024-04-10
MX2023005678A (es) 2023-05-26
US11766443B2 (en) 2023-09-26
JP7810743B2 (ja) 2026-02-03
CA3200710A1 (en) 2022-05-19
AU2021379248A9 (en) 2024-10-10
CL2024000317A1 (es) 2024-07-12
JOP20230107A1 (ar) 2023-05-16
AU2021379248A1 (en) 2023-06-22
IL302769A (en) 2023-07-01
CL2023001361A1 (es) 2023-11-03
SA523440809B1 (ar) 2024-10-08
JP2023521200A (ja) 2023-05-23
PE20231855A1 (es) 2023-11-21
EP4244229A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
ECSP21012498A (es) COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET
CO2021014155A2 (es) Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2
CL2021001406A1 (es) Derivados de amino triazolo quinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso.
ECSP21034668A (es) Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento de cáncer
PA8587101A1 (es) Nuevos derivados de dihidropirimido [4,5-d] pirimidinona sustituida por amiino, fabricacion y uso de los mismos como agentes farmaceuticos
PA8680701A1 (es) Derivados de oxindol
MX2016010519A (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
PE20210856A1 (es) Derivados sustituidos de la carboxamida dihidropirazolo pirazina
CL2025001220A1 (es) Análogos, sales, composiciones y métodos de uso de la psilocibina
CL2019002601A1 (es) Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos.
CL2023001574A1 (es) Uso de activadores de sgc para el tratamiento de enfermedades oftalmológicas
DOP2023000090A (es) Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas
CL2023001244A1 (es) Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
MX2022000099A (es) Compuestos para el tratamiento del cancer.
UY28535A1 (es) Derivados de bencimidazol, composiciones que los contienen, preparacion y usos de los mismos.
MX2020013895A (es) Agentes inhibidores de ask1.
AR049343A1 (es) Derivados tioeter, su obtencion y utilizacion de los mismos como agentes farmaceuticos
AR131509A1 (es) Inhibidores del inflamasoma nlrp3
CO2025010725A2 (es) Compuestos moduladores de receptores de dopamina d3/d2
UY27534A1 (es) Amidas de ácido antranílico y uso farmacológico de las mismas.
ECSP045092A (es) Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf